Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35290593/
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction,...
Conclusions/Relevance: Cardiac remodeling encompasses molecular, cellular, and interstitial changes that result in favorable changes in the mass, geometry, size, and function of the heart. The pathophysiological mechanisms of adverse cardiac remodeling are related to increased apoptosis and necrosis, decreased autophagy, impairments of...
Share
Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway
Source : https://www.frontiersin.org/articles/10.3389/fphys.2022.817542/full
Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective...
Conclusions: The results of the 5-Aminoimidazole-4-carboxamide1-β-D-ribofuranoside (AIACR) intervention in HL7702 cells were consistent with those of empagliflozin treatment, and the effects of empagliflozin were abolished by compound C. In summary, empagliflozin could maintain glucose homoeostasis by reducing gluconeogenesis and increasing...
Share
Automated Insulin Delivery (AID) with SGLT2i Combination Therapy in Type 1 Diabetes
Source : https://www.liebertpub.com/doi/10.1089/dia.2021.0542
Use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as adjunct therapy to insulin in type 1 diabetes (T1D) has been previously studied. In this study, we present data from the first...
Conclusion/Relevance: Interpretation In an eight-week outpatient study, addition of 5 mg daily empagliflozin to commercially available AID or PLGS systems significantly improved daytime glucose control in individuals with T1D, without increased hypoglycaemia risk. However, the risk of ketosis and ketoacidosis remains. Therefore, future studies...
Share
Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update
Source : https://www.tandfonline.com/doi/abs/10.1080/14656566.2022.2047647?journalCode=ieop20
ABSTRACT Despite considerable advances in the treatment of heart failure with reduced ejection fraction (HFrEF) over the last 60 years, mortality and morbidity remains high. Fortunately, in the last years,...
Relevance: The authors provide an overview of recent developments in HF treatment and bring the recommendations in the HF guidelines of the European Society of Cardiology into perspective.
Share
Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35270028/
The profile of sphingomyelin and its metabolites shows changes in the plasma, organs, and tissues of patients with cardiovascular, renal, and metabolic diseases. The objective of this study was to...
Conclusion/Relevance: Our results suggest that empagliflozin downregulates the interaction of the de novo pathway and the catabolic pathway of sphingolipid metabolism in the diabetes, whereas in Ang II-dependent hypertension, it only downregulates the sphingolipid catabolic pathway.
Share